Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K.
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia.
Oh BLZ, Vinanica N, Wong DMH, Campana D.
Haematologica. 2024 Jun 1;109(6):1677-1688. doi: 10.3324/haematol.2023.283848.
scRNA-seq reveals an immune microenvironment and JUN-mediated NK cell exhaustion in relapsed T-ALL.
Liu Y, Du Z, Li L, Huang J, Liu S, Lu B, Duan Y, Cheng Y, Li T, Zhang J, Mo J, Yang Y, Wang W, Zou H, Liang T, Jiang M, Yang M, Chen Y, Ouyang C, Chen C.
Cell Rep Med. 2025 May 20;6(5):102098. doi: 10.1016/j.xcrm.2025.102098. Epub 2025 Apr 29.
Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.
Bexte T, Botezatu L, Miskey C, Gierschek F, Moter A, Wendel P, Reindl LM, Campe J, Villena-Ossa JF, Gebel V, Stein K, Cathomen T, Cremer A, Wels WS, Hudecek M, Ivics Z, Ullrich E.
Mol Ther. 2024 Jul 3;32(7):2357-2372. doi: 10.1016/j.ymthe.2024.05.022. Epub 2024 May 14.
T and NK lymphoblastic leukemia/lymphoma: Report from the 2023 SH/EAHP Workshop.
Weinberg OK, Bueso-Ramos CE, Kanagal-Shamanna R.
Am J Clin Pathol. 2025 Jul 11;164(1):26-35. doi: 10.1093/ajcp/aqaf015.
CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.
Yang N, Zhang C, Zhang Y, Fan Y, Zhang J, Lin X, Guo T, Gu Y, Wu J, Gao J, Zhao X, He Z.
J Transl Med. 2024 Mar 13;22(1):274. doi: 10.1186/s12967-024-04990-6.
Key candidate genes and pathways in T lymphoblastic leukemia/lymphoma identified by bioinformatics and serological analyses.
Ren Y, Liang H, Huang Y, Miao Y, Li R, Qiang J, Wu L, Qi J, Li Y, Xia Y, Huang L, Wang S, Kong X, Zhou Y, Zhang Q, Zhu G.
Front Immunol. 2024 Feb 23;15:1341255. doi: 10.3389/fimmu.2024.1341255. eCollection 2024.
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, Rouce RH, Bao G, Brenner MK, Mamonkin M.
Blood. 2017 Jul 20;130(3):285-296. doi: 10.1182/blood-2017-01-761320. Epub 2017 May 24.
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening.
Ramos A, Koch CE, Liu-Lupo Y, Hellinger RD, Kyung T, Abbott KL, Fröse J, Goulet D, Gordon KS, Eidell KP, Leclerc P, Whittaker CA, Larson RC, Muscato AJ, Yates KB, Dubrot J, Doench JG, Regev A, Vander Heiden MG, Maus MV, Manguso RT, Birnbaum ME, Hemann MT.
Nat Commun. 2023 Dec 5;14(1):8048. doi: 10.1038/s41467-023-43790-2.
Natural killer cells.
Kay NE.
Crit Rev Clin Lab Sci. 1986;22(4):343-59. doi: 10.3109/10408368509165790.
